Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romiplostim biosimilar - Qilu Pharmaceutical

Next Previous
Drug Profile

Romiplostim biosimilar - Qilu Pharmaceutical

Alternative Names: N01; QL-0911; Romiplostim-N01; TPO receptor agonist - Qilu Pharmaceutical

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Developer Peking University People's Hospital; Qilu Pharmaceutical; The First Affiliated Hospital of Soochow University
  • Class Antianaemics; Carrier proteins; Immunotherapies; Radioprotectives; Recombinant fusion proteins; Skin disorder therapies
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Thrombocytopenia
  • Phase II Aplastic anaemia; Idiopathic thrombocytopenic purpura

Most Recent Events

  • 18 Aug 2026 Fudan University plans a phase II trial for Thrombocytopenia (Chemotherapy-induced, Treatment-experienced) in China in August 2026 (SC, Injection) (NCT07771881)
  • 02 Jun 2026 Efficacy and adverse events data from a phase II trial in Thrombocytopenia presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 29 May 2026 Efficacy and adverse events data from a clinical trial in Chemotherapy induced thrombocytopenia presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top